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Hsp90 is a molecular chaperone responsible for the assembly and regulation
of many cellular client proteins. In particular, Trap1, a mitochondrial Hsp90
homologue, plays a pivotal role in maintaining mitochondrial integrity,
protecting against apoptosis in cancer cells. The N (N-terminal)-M (middle)
domain of human Trap1 was crystallized in complex with Hsp90 inhibitors (PU-
H71 and BIIB-021) by the hanging-drop vapour-diffusion method at pH 6.5 and
293 K using 15% PEG 8K as a precipitant. Diffraction data were collected from
crystals of the Trap1–PU-H71 (2.7 A˚) and Trap1–BIIB-021 (3.1 A˚) complexes to
high resolution at a synchrotron-radiation source. Preliminary X-ray diffraction
analysis revealed that both crystals belonged to space group P41212 or P43212,
with unit-cell parameters a = b = 69.2, c = 252.5 A˚, and contained one molecule
per asymmetric unit according to Matthews coefficient calculations.
1. Introduction
Heat-shock protein 90 (Hsp90) is an essential molecular chaperone
that has ATPase activity and regulates protein folding (Zhao et al.,
2005). Accumulating data have revealed that the client proteins for
Hsp90 chaperones include cell-cycle proteins such as Cdc2, Cdk4,
Cdk6 and Cdk9, signalling kinases such as HRI, Raf-1, Erb2 and
Her2, and nuclear hormone receptors such as ER, AR and GR
(Chiosis et al., 2004; Pratt & Toft, 2003; Shao et al., 2001). There
are organelle-specific Hsp90 homologues, which include glucose-
regulated protein 94 (Grp94, endoplasmic reticulum) and tumour
necrosis factor receptor-associated protein 1 (Trap1, mitochondria),
as well as a cytoplasmic Hsp90 (Chen et al., 2005; Johnson, 2012;
Taipale et al., 2010). The architectures and molecular mechanisms
of the ATPase activities of Hsp90 and Grp94 have been studied
extensively by X-ray crystallography and biochemical experiments
from bacteria to mammals (Ali et al., 2006; Dollins et al., 2007; Huai et
al., 2005; Pearl & Prodromou, 2006). The studies have elucidated that
members of the Hsp90 family form a homodimer consisting of three
distinct domains: an N-terminal ATP-binding domain (N-domain), a
middle domain (M-domain) responsible for client-protein binding
and catalytic reaction, and a C-terminal dimerization domain
(C-domain). The structural studies also reveal a complex mechanism
for ATPase-coupled conformational changes, which is critical for
their chaperone activities (Krukenberg et al., 2011).
Trap1 was first identified as a binding partner of tumour necrosis
factor receptor 1 (TNFR1) using a yeast two-hybrid system (Song et
al., 1995). Human Trap1 contains 704 amino acids and shares struc-
tural and functional features with cytosolic Hsp90 and Grp94.
Recently, crystal structures of ATP analogues bound to Trap1 from
zebrafish have been solved and revealed that the asymmetric
protomer organization of the Trap1 dimer plays a critical role in the
ATPase cycle (Lavery et al., 2014). Trap1 has emerged as a cancer
therapeutic target because the activity of Trap1 has important
implications for cytoprotection from DNA damage and apoptosis
induced by oxidative stress conditions (Hua et al., 2007; Kang, 2012;
Montesano Gesualdi et al., 2007; Kang et al., 2009).
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To better understand the molecular mechanism of how Hsp90
ATPase inhibitors are specifically recognized by Trap1 and to design
new inhibitors that exclusively target Trap1, it is essential to deter-
mine the three-dimensional structures of Trap1–inhibitor complexes.
Here, we describe the purification and crystallization procedure of
human Trap1 (N-M domain) complexed with the well known Hsp90
ATPase inhibitors PU-H71 and BIIB-021 and provide preliminary
X-ray diffraction data.
2. Materials and methods
2.1. Macromolecule production
For crystallographic studies, genes encoding full-length human
Trap1 (residues 60–704, hereafter referred to as fTrap1) excluding
the N-terminal mitochondrial targeting signal (residues 1–59) and a
truncated version of Trap1 (residues 60–561, hereafter referred to as
tTrap1) were amplified from an MGC full-length clone (Invitrogen)
using PCR. The primers were forward, 50-GCCGTAGGATCCAG-
CACGCAGACCGCCGAGGAC-30, and reverse, 50-GCCGTAATT-
GCGGCCGCTCAGTGTCGCTCCAGGGCCTT-30 for fTrap1 and
50-GCCGGTCGACTCACTCCTTGTAGTGATCCACGAC-30 for
tTrap1. The amplified gene was digested with the restriction enzymes
BamHI and NotI (704)/SalI (561) at the N-terminus and C-terminus,
respectively, and ligated into modified pET-Duet vector (Novagen)
with an N-terminal histidine tag (6His). This construct encoded a
His6-Trap1 protein with Tobacco etch virus (TEV) protease recog-
nition sequences (ENLYGQS) between His6 and Trap1 (Table 1).
The protein-expression and purification methods were the same
for both fTrap1 and tTrap1. The plasmid encoding human His6-Trap1
was transformed into Escherichia coli strain BL21 (DE3) for protein
expression. A 5 ml seed of an overnight bacterial culture was trans-
ferred into 1000 ml fresh LB medium containing ampicillin
(50 mg ml1) and grown at 310 K with vigorous shaking. When the
cell density reached the mid-log phase (OD600 of 0.5–0.8), isopropyl
-d-1-thiogalactopyranoside was added to a final concentration of
0.2 mM. The cells were further cultured at 295 K for 15 h after
induction to express the protein and were harvested by centrifugation
at 10 000g for 15 min at 277 K. The pellet was resuspended in buffer
A (25 mM sodium phosphate, 400 mM sodium chloride pH 7.4) plus
0.5 mM phenylmethylsulfonyl fluoride. The purification procedure
comprised three consecutive chromatography steps including affinity,
ion-exchange and size-exclusion chromatography. The cells were
lysed by sonication on ice and the lysate was clarified by centri-
fugation at 40 000g for 50 min at 277 K. After centrifugation, the
supernatant was loaded onto an Ni-charged chelating column
(HiTrap Chelating column, GE Healthcare) equilibrated with buffer
A. After washing with buffer B (25 mM sodium phosphate, 400 mM
sodium chloride, 50 mM imidazole pH 7.4), the bound Trap1 protein
was eluted from the column using buffer C (25 mM sodium phos-
phate, 300 mM sodium chloride, 400 mM imidazole pH 7.4). The
eluted protein was dialyzed against 25 mM Tris, 100 mM sodium
chloride, 5 mM dithiothreitol (DTT) pH 8.5 overnight to remove
imidazole. During dialysis, the N-terminal His6 tag was removed with
TEV protease. The dialyzed protein solution was diluted with buffer
D (25 mM Tris, 5 mM DTT pH 8.5) to reduce the concentration of
sodium chloride to 50 mM and applied onto a 5 ml HiTrap Q column
(GE Healthcare) pre-equilibrated with buffer D. After washing with
buffer D (five column volumes), the protein was eluted with a linear
gradient of 0–100% buffer E (25 mM Tris, 1 M sodium chloride, 5 mM
DTT pH 8.5) in 30 column volumes. The protein was further purified
with a Superdex 200 HR 16/60 gel-filtration column (GE Healthcare)
equilibrated with buffer F (25 mM Tris, 150 mM sodium chloride,
5 mM DTT pH 7.5). The eluted Trap1 protein was finally concen-
trated to 20 mg ml1 using an Amicon Ultra-15 centrifugal filter
(50 kDa molecular-weight cutoff, Millipore) and flash-frozen in liquid
nitrogen for storage. All purification steps were carried out at 277 K
and were monitored by SDS–PAGE.
2.2. Crystallization
For the crystallization of Trap1–inhibitor complexes, two Hsp90
inhibitors (PU-H71 and BIIB-021) were dissolved in dimethyl sulf-
oxide (DMSO, Sigma). Prior to crystallization experiments, the Trap1
(full-length and truncated) protein was mixed with inhibitor in a 1:2
molar ratio for 50 min on ice. To minimize the damage to the protein
by DMSO, we diluted the protein solution with buffer F, resulting in a
final concentration of 9 mg ml1 dissolved in less than 3% DMSO.
Initial hanging-drop vapour-diffusion crystallization screening was
performed at both 277 and 293 K using a 24-well VDX crystallization
plate (Hampton Research) and commercially available screening
solutions including Crystal Screen, Crystal Screen 2, Grid Screen
(Hampton Research) and Wizard (Emerald Bio). Crystallization
drops were prepared by mixing 1 ml Trap1 protein complexed with
inhibitors and 1 ml screen solution. Rod-shaped crystals of fTrap1–
PU-H71 were initially obtained using well solution consisting of
1.7 M sodium potassium phosphate, 5 mM DTT pH 6.5. tTrap1–
PU-H71 and tTrap1–BIIB-021 were crystallized in the same crystal-
lization buffer comprising 16% polyethylene glycol (PEG) 8000,
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Table 1
Macromolecule-production information.
Source organism Homo sapiens
DNA source MGC full-length clone (Invitrogen)
Forward primer 50-GCCGTAGGATCCAGCACGCAGACCGCCGAGGAC-30
Reverse primers
fTrap1 50-GCCGTAATTGCGGCCGCTCAGTGTCGCTCCAGGGCCTT-30
tTrap1 50-GCCGGTCGACTCACTCCTTGTAGTGATCCACGAC-30
Expression vector pET-Duet
Expression host Escherichia coli BL21(DE3)
UniProt accession No. Q12931
Table 2
Data collection and processing.
Values in parentheses are for the highest resolution shell.
tTrap1–PU-H71 tTrap1–BIIB-021
Beamline 5C, PAL 5C, PAL
Wavelength (A˚) 0.97953 0.97953
Temperature (K) 100 100
Detector ADSC Q315r ADSC Q315r
Rotation range per image () 1 1
Total rotation range () 50 60
Exposure time per image (s) 1 1
Space group P41212 or P43212 P41212 or P43212
a, b, c (A˚) 69.22, 69.22, 252.52 69.46, 69.46, 252.81
, ,  () 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Resolution range (A˚) 35.0–2.70 (2.75–2.70) 35.0–3.10 (3.15–3.10)
Total No. of reflections 66641 53941
No. of unique reflections 17708 (864) 11899 (594)
Completeness (%) 99.4 (99.8) 98.5 (98.7)
Multiplicity 3.8 (3.9) 4.5 (4.7)
hI/(I)i 24.5 (2.7) 20.1 (4.0)
Rmerge† (%) 7.3 (56.1) 10.0 (47.6)
† Rmerge = 100 
P
hkl
P
i jIiðhklÞ  hIðhklÞij=
P
hkl
P
i IiðhklÞ, where Ii(hkl) is the ith
measurement and hI(hkl)i is the weighted mean of all measurements of I(hkl) for Miller
indices hkl.
100 mM sodium cacodylate, 5 mM DTT pH 6.5. The initial crystal-
lization condition was optimized by varying the protein concentra-
tion, the precipitant concentration and the pH and by using Additive
Screen (Hampton Research).
2.3. Data collection and processing
For X-ray diffraction studies, crystals were transferred to a cryo-
protection solution comprising reservoir buffer plus 30% glycerol and
flash-cooled in liquid nitrogen. X-ray data were collected from the
cooled crystals on beamline 5C of Pohang Accelerator Laboratory
(PAL), Pohang, Republic of Korea using a Q315r CCD detector.
X-ray diffraction data were processed with HKL-2000 (Otwinowski
& Minor, 1997). Complete data sets for the tTrap1–PU-H71 and
tTrap1–BIIB-021 complexes were collected to 2.7 and 3.1 A˚ resolu-
tions, respectively. However, fTrap1–PUH71 diffracted too poorly to
collect complete data. The data-collection statistics are summarized
in Table 2.
3. Results and discussion
The organelle-specific Hsp90 homologue proteins such as cytosolic
Hsp90 and ER-resident Grp94 have previously been crystallized and
their structures have been determined (Ali et al., 2006; Dollins et al.,
2007). To crystallize a Trap1 protein, which is a mitochondrial Hsp90
homologue, we constructed both the full-length (fTrap1; residues
60–704) and a truncated version (tTrap1; residues 60–561) of human
Trap1. fTrap1 and tTrap1 were expressed as His6-tagged proteins at
the N-terminus and were purified to homogeneity using the same
procedures. The purity of proteins at the final purification step was at
least 95% as monitored by SDS–PAGE (Fig. 1). We could obtain
20 mg of pure protein per litre of bacterial culture broth. Before
crystallization trials, the purified proteins were mixed with Hsp90
inhibitors including PU-H71 and BIIB-021, which are well known
small molecules that specifically target the Hsp90 ATPase domain.
Rod-shaped crystals of the fTrap1–inhibitor complexes were obtained
in a crystallization condition consisting of 1.7 M sodium potassium
phosphate, 0.1 M HEPES, 0.4 M potassium chloride pH 7.5 at 293 K
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Figure 1
Proteins and inhibitors used in crystallization. (a) SDS–PAGE analysis showing purified human Trap1; lane 1, fTrap1 (residues 60–704); lane 2, tTrap1 (residues 60–561).
Lane M contains molecular-weight marker (AccuLadder Protein Size Marker, Bioneer; labelled in kDa). (b) The purine-based Hsp90 inhibitors complexed with Trap1.
Figure 2
Crystals of human Trap1–inhibitor complexes. (a) Crystals of the human fTrap1–PU-H71 complex grown in 1.7 M sodium potassium phosphate, 0.1 M HEPES, 0.4 M
potassium chloride pH 7.5 (maximum dimensions 0.02  0.02  0.2 mm). (b) Crystals of the human tTrap1–PU-H71 complex grown in 16% PEG 8K, 100 mM calcium
acetate, 100 mM sodium cacodylate pH 6.5 (maximum dimensions 0.05  0.05  0.25 mm). (c) Crystals of the human tTrap1–BIIB-021 complex grown in the same condition
as in (b).
by the hanging-drop vapour-diffusion method. The dimensions of
the crystals were about 0.02  0.02  0.2 mm (Fig. 2a). The tTrap1–
inhibitor mixture was crystallized in a reservoir buffer consisting of
16% PEG 8K, 0.1 M sodium cacodylate, 5 mM DTT pH 6.5 at 293 K.
The initial condition was improved to give diffraction-quality crystals
by adding 0.1 M calcium acetate and removing the reducing agent
DTT (Fig. 2b). No difference in crystal shape was found between the
PU-H71-bound and BIIB-021-bound crystals. From this observation,
we propose that there is no significant structural difference between
PU-H71–Trap1 and BIIB-021–Trap1. In order to collect X-ray
diffraction data, we cryocooled crystals using cryoprotection solution
consisting of reservoir solution plus 30% glycerol. We collected X-ray
diffraction data on beamline 5C at PAL. While the crystals of the
fTrap1–inhibitor complex diffracted to a maximum of 10 A˚ reso-
lution, the tTrap1–inhibitor complex crystals displayed good-quality
diffraction patterns. The crystals of PU-H71–tTrap1 and BIIB-021–
tTrap1 diffracted to maximum resolutions of 2.7 and 3.1 A˚, respec-
tively (Fig. 3). The crystals belonged to space group P41212 or P43212,
with unit-cell parameters a = b = 69.2, c = 252.5 A˚ (Table 2).
Assuming the presence of only one molecule per asymmetric unit, the
Matthews coefficient (VM) was estimated to be 2.64 A˚
3 Da1, with a
solvent content of 53% (Matthews, 1968). While we were attempting
to solve the phase problem for the crystals, structures were deter-
mined of full-length zebrafish Trap1 in complex with ATP analogues
(Lavery et al., 2014). Human Trap1 has 74% sequence identity to
zebrafish Trap1. We are currently trying to solve the structure of the
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Figure 3
X-ray diffraction images. X-ray diffraction patterns collected from a single crystal of (a) the tTrap1–PU-H71 complex and (b) the tTrap1–BIIB-021 complex. The diffraction
images were obtained using a synchrotron-radiation source. The maximum observed resolution for the tTrap–PU-H71 and tTrap1–BIIB-021 complexes is 2.7 and 3.1 A˚,
respectively.
human tTrap1–Hsp90 inhibitor complexes using molecular-replace-
ment methods with the zebrafish Trap1 structure (PDB entry 4ivg;
Lavery et al., 2014) as a search model.
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